Plain-English translation of NCT07225985 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether a new combination approach — using and chemotherapy drugs along with radiation to your whole body, followed by a transplant of healthy stem cells from a donor — can help people with T-cell lymphoma that either didn't respond to treatment or has returned. The goal is to prepare your body to accept the donor cells, which can help fight the cancer and replace damaged blood-forming cells.
Standard treatments don't work well enough for all patients with this type of aggressive lymphoma, especially when it comes back or resists initial therapy. This trial is testing whether this new medication combination, combined with stem cell transplant, can be more effective while being tolerable for patients.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy infusions over several days, followed by radiation to your entire body, and then a transplant of stem cells from your matched donor on day 0 of the study. Before and during treatment, you will undergo various tests including imaging scans, heart function tests, blood draws, and bone marrow biopsies to monitor your health and how well the transplant is working. After your hospital stay, you will return for follow-up visits at 6 months, 9 months, 1 year, 1.5 years, and 2 years to ensure the transplant is successful and to watch for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States